Josh Jennings
Stock Analyst at Morgan Stanley
(2.65)
# 2,027
Out of 4,749 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $42.84 | +23.72% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $280.03 | +7.13% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $4.09 | +389.00% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $19.88 | +216.90% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.99 | +607.07% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $73.22 | -45.37% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $42.84
Upside: +23.72%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $280.03
Upside: +7.13%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $4.09
Upside: +389.00%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $19.88
Upside: +216.90%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.99
Upside: +607.07%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $73.22
Upside: -45.37%